Use of Mecamylamine in the Management of Hypertension
Overview
Authors
Affiliations
Quadri M, Bagdas D, Toma W, Stokes C, Horenstein N, Damaj M J Pharmacol Exp Ther. 2018; 367(2):203-214.
PMID: 30111636 PMC: 7593094. DOI: 10.1124/jpet.118.249904.
Baakman A, Alvarez-Jimenez R, Rissmann R, Klaassen E, Stevens J, Goulooze S Br J Clin Pharmacol. 2017; 83(8):1676-1687.
PMID: 28217868 PMC: 5510063. DOI: 10.1111/bcp.13268.
Rahman S, Zhang Z, Papke R, Crooks P, Dwoskin L, Bardo M Br J Pharmacol. 2007; 153(4):792-804.
PMID: 18059317 PMC: 2259212. DOI: 10.1038/sj.bjp.0707612.
DEPRESSION OF THE VASOMOTOR CENTRE BY MECAMYLAMINE, INDEPENDENT OF ITS GANGLION-BLOCKING ACTIVITY.
Bhargava K, DHAWAN K Br J Pharmacol Chemother. 1963; 21:39-44.
PMID: 14066149 PMC: 1703867. DOI: 10.1111/j.1476-5381.1963.tb01499.x.
Treatment of hypertension with pentolinium and mecamylamine.
Sears H, Snow P, Houston I Br Med J. 1959; 1(5120):462-5.
PMID: 13629020 PMC: 1992771. DOI: 10.1136/bmj.1.5120.462.